New Therapeutic Developments in Hematological Malignancies

Dear Colleagues,

Hematological malignancies represent 10% of cancers worldwide, and their frequency has increased over the past two decades. With two thirds affecting the lymphoid lineage, many therapeutic developments are still required, and some have recently emerged. Combinatorial chemotherapies with more less targeted therapies directed against the oncogene itself such as activated or chimeric kinases or indirectly against regulators such as immunological (immune check points) or apoptotic (anti-Bcl2) pathways are still developed. In addition, to complete stem cell transplantation, new cell therapies have even emerged, using genetically modified cells to initiate immune responses against cancer cells such as Car-T cells.

The advent of these recent developments requires both conceptually and rationally resuming the various strategies initiated within the framework of the therapeutic management of hematologic malignancies. This Special Issue is devoted to all these new strategies and their development to improve these future therapies and patient care.

Dr. Jean-Max Pasquet
Dr. Fabienne Meggetto
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.